# Convergent AI for Precise Breast Cancer Risk Assessment

> **NIH NIH R01** · METHODIST HOSPITAL RESEARCH INSTITUTE · 2021 · $503,083

## Abstract

ABSTRACT
 Breast cancer continues to be one of the leading causes of cancer death among women in the United
States, despite the advances made in the identification of prognostic and predictive markers for breast cancer
treatment. Mammographic reporting is the first step in the screening and diagnosis of breast cancer. Abnormal
mammographic findings such as a mass, abnormal calcifications, architectural distortion, and asymmetric
density can lead to a cancer diagnosis. The American College of Radiology developed the Breast Imaging
Reporting and Data System (BI-RADS) lexicon to standardize mammographic reporting to facilitate biopsy
decision-making. However, application of the BI-RADS lexicon has resulted in substantial inter-observer
variability, including inappropriate term usage and missing data. This observer variability has lead in part to a
considerable variation in the rate of biopsy across the US, with a majority of breast biopsies ultimately found to
be benign lesions. Hence, there is the need for a system that can better stratify the risk of cancer and define a
more optimum threshold for biopsy. To address this need, we propose to develop an intelligent-augmented risk
assessment system for breast cancer management based on multimodality image and clinical information with
deep learning and data mining techniques.
 This study aims to develop a well-defined, novel risk assessment system incorporating multi-modality
datasets with a novel predictive model that outputs a probability measure of cancer that is more clinically
relevant and informative than the six discrete BI-RADS scores. Using mammographic or breast ultrasound BI-
RADS reporting signatures and radiomics features, a predictive model that is more precise and clinically
relevant may be developed to target well-characterized and defined specific biopsy patient subgroups rather
than a broad heterogeneous biopsy group. Our proposed technique entails a novel strategy using Natural
Language Processing to extract pertinent clinical risk factors related to breast cancer from vast amounts of
patient charts automatically and integrate them with corresponding image-omics data and radiologist-
generated reports. We will extract and quantitate image features from both large amounts of mammography
and breast ultrasound images and combine them with the radiology reports and pertinent clinical risk profile
and other patient characteristics to generate a risk assessment score to aid radiologists and oncologists in
breast cancer risk assessment and biopsy decisions. Such a web-based application tool will be the first breast
cancer risk assessment system based on integrative radiomics data augmented by AI methods. The iBRISK
tool will enhance engagement between the patient and clinician for making an informed decision on whether or
not to biopsy.
 Our hypothesis is that BI-RADS reports and the imaging metrics contain significant features for the breast
cancer risk assessment and biopsy decision-maki...

## Key facts

- **NIH application ID:** 10172878
- **Project number:** 5R01CA251710-02
- **Recipient organization:** METHODIST HOSPITAL RESEARCH INSTITUTE
- **Principal Investigator:** STEPHEN TC WONG
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $503,083
- **Award type:** 5
- **Project period:** 2020-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10172878

## Citation

> US National Institutes of Health, RePORTER application 10172878, Convergent AI for Precise Breast Cancer Risk Assessment (5R01CA251710-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10172878. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
